Cargando…
Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study
Objectives To describe the content of non-public complete response letters issued by the US Food and Drug Administration (FDA) when they do not approve marketing applications from sponsors (drug companies) and to compare them with the content any subsequent press releases issued by those sponsors De...
Autores principales: | Lurie, Peter, Chahal, Harinder S, Sigelman, Daniel W, Stacy, Sylvie, Sclar, Joshua, Ddamulira, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462714/ https://www.ncbi.nlm.nih.gov/pubmed/26063327 http://dx.doi.org/10.1136/bmj.h2758 |
Ejemplares similares
-
Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants
por: Chahal, Harinder Singh, et al.
Publicado: (2021) -
Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022) -
FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023) -
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016) -
Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)